Dose–response relationship between docosahexaenoic acid (DHA) intake and lower rates of early preterm birth, low birth weight and very low birth weight. (November 2018)

• Record Type: Journal Article
• Authors: Carlson, Susan E.; Gajewski, Byron J.; Alhayek, Sibelle; Colombo, John; Kerling, Elizabeth H.; Gustafson, Kathleen M.
• Is Part Of: Prostaglandins, leukotrienes, and essential fatty acids. Volume 138(2018)
• Page Start: 1
• Page End: 5
• Publication Date: 2018-11
• Subjects: Placebo -- Docosahexaenoic acid -- Preterm birth -- Compliance -- Birth weight; DHA docosahexaenoic acid -- ePTB early preterm birth (<34 weeks gestation) -- VLBW very low birth weight; Lipids -- Periodicals; Unsaturated fatty acids -- Periodicals; Prostaglandins -- Periodicals; Leukotrienes -- Periodicals; Fatty Acids, Unsaturated -- Periodicals; Acides gras insaturés -- Périodiques; Prostaglandines -- Périodiques; Leucotriènes -- Périodiques; Lipides -- Périodiques; 612.01577
• DOI: 10.1016/j.plefa.2018.09.002
• Languages: English
• ISSNs: 0952-3278

Abstract

Abstract: As previously reported, intention-to-treat findings from our phase III randomized clinical trial found that a supplement of 600 mg docosahexaenoic acid (DHA)/day during the last half of pregnancy reduced the incidence of early preterm birth (ePTB, &lt;34 weeks gestation) and very low birth weight (VLBW &lt; 1500 g) offspring. Given the potentially immense clinical significance of these findings, the goal of this secondary analysis was to (1) identify maternal characteristics related with capsule intake (i.e. DHA dose exposure) and (2) determine if DHA dose was associated with low (&lt;2500 g) and very low birth weight after controlling for any relevant maternal characteristics. Three hundred forty-five pregnant mothers were recruited from hospitals in the Kansas City metropolitan area between 2006 and 2011. Most participants ( n = 299) were from the phase III trial mentioned above, but we also included 46 participants from a second smaller, randomized trial that utilized an identical intervention design and was conducted concurrent to the larger trial. Both trials assigned participants to either 3 daily capsules of vegetable oil without DHA ( n = 169) or 3 daily capsules of 200 mg DHA each ( n = 176). Total capsules consumed was recorded by pharmacy supervised capsule count or participant self-report when needed. Maternal age, education, race and gestational age at delivery as well as infant birth weight were available for both trials. A Bayesian linear model indicated capsule intake increased with maternal age ( p = 0.0100) and years of education ( p = 0.0002). A Bayesian bivariate mixture-model associated capsule intake with simultaneous lower probability of ePTB, low birth weight (LBW, &lt;2500 g) and VLBW ( p = 0.0327). This, in conjunction with the positive findings in the clinical trial, support the need for future research to examine intervention methods to improve capsule compliance strategies in younger and less educated mothers.